ImmunoCellular Announces Data Monitoring Committee Recommends Continuation of ICT-107 Phase II Trial

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”)

announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion. The trial design for the ICT-107 study provides for the interim analysis to be conducted by the independent DMC after 32 events (patient deaths) are reached. ImmunoCellular remains blinded to the actual results and details of the interim analysis and any patient data pertaining to the ongoing trial. No additional interim analyses are planned. The Company anticipates that the phase II trial should be completed by the end of 2013.